Drugmakers and contract drug manufacturers are stepping up their investments in antibody-drug conjugates prompted by the huge sales potential of this new class of cancer drugs. Roche Holding's breast cancer drug Kadcyla and Seattle Genetics' lymphoma treatment Adcetris are the only ADCs available on the market, and others are largely in early development, but the market is predicted to expand to $9 billion by 2023. Roche and MedImmune are among those working on their ADC pipelines. Contract manufacturers such as Carbogen Amcis and Piramal Healthcare are investing in their ADC production capabilities.

Related Summaries